Regulation Of The UAE Pharmaceutical Industry

The United Arab Emirates aims to strengthen its position as a leading pharmaceutical hub. In this regard, the UAE is introducing a more transparent and harmonized regulatory framework for the pharmaceutical sector. One of the key measures contributing to the improvement of regulation in the UAE was the adoption of Federal Law No. 38 of 2024 on the regulation of the circulation of medical products, including medicines and medical equipment, as well as the activities of pharmacists and pharmaceutical institutions.

‍

This law expanded the list of regulated medical products and persons involved in the pharmaceutical sector whose activities are subject to regulation. The requirements for medical products have now been clarified and expanded to include, for example, biopharmaceuticals, BAS, chemical precursors, and requirements for the marketing of innovative products, advertising and promotion of medical products, and the activities of biobanks, marketing offices, and other organisations.

‍

The alert provides an overview of the main provisions of Law No. 38 and other features of the regulation of the pharmaceutical sector in the UAE.

‍